CTIS2022-501312-34-01进行中（未招募）1 期
The Intertransverse Process Block - Single or Multiple Injection? A randomised, procedure related, blinded crossover trial in healthy volunteers - ZUH-ITP-MBCS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •Male sex, Age = 18 years at the date of inclusion, American Associations of Anaesthesiologist (ASA) class I-II, Have received thorough information, orally and in written form, and signed the Informed Consent” form on participation in the study., Weight > 52,5 kilograms (chosen due to the international maximal single dose of Ropivacaine (3mg/kg)
排除标准
- •Substantial co-morbidity: American Associations of Anaesthesiologist (ASA) class > II, Daily intake of analgesics (investigators decision), Alcohol and/or drug overuse (investigators decision), Previous thoracic trauma or thoracic surgery, Previous/current piercing of the nipple of any kind on blockade side, Tattoos on the thorax (according to the investigators decision), Any systemic muscular or neuromuscular disease, Any use of vasodilatory substance (investigators decision), Local infection at the site of injection or systemic infection, Difficult sonoanatomical visualisation of the target area (SCTL, ITTC etc.) necessary for the block execution, Severe hypovolemia, Inability to speak and understand Danish, Inability to cooperate, Allergy to study drugs
研究者
相似试验
进行中（未招募）
1 期
ITP BLOCK FOR MINOR BREAST CANCER SURGERYMedDRA version: 20.0Level: PTClassification code: 10006187Term: Breast cancer Class: 100000004864Breast cancerCTIS2022-501312-34-00Zealand University Hospital30
招募中
4 期
ITP Block: Single or Multiple Injection?Anesthesia, LocalNCT05753397Zealand University Hospital12
进行中（未招募）
1 期
A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEEUCTR2006-000936-28-IEAstellas Pharma GmbH125
进行中（未招募）
1 期
A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEEUCTR2006-000936-28-FRAstellas Pharma GmbH125
进行中（未招募）
不适用
A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEStable, adult kidney transplant recipients (= 12 months post transplant) who are currently treated with Prograf.MedDRA version: 7.0Level: LLTClassification code 10024716EUCTR2006-000937-37-DEAstellas Pharma GmbH125